65,437 trials
Covid19 · SARS-CoV Infection · Corona Virus Infection
Primary: Number of Unsolicited Adverse Events in Healthy Participants Challenged With Wild Type SARS-CoV-2 — 45 Unsolicited Adverse Events
Atrial Fibrillation · Atrial Flutter · Ventricular Tachycardia
Primary: Percentage of Subjects With a Primary Safety Event — 2 Participants
Muscle Weakness
Primary: Change in Body Satisfaction Questionnaire From Baseline to 1-month Post-Treatment Follow-up Visit — 8.6 units on a scale
Parkinson Disease
Primary: Unified Parkinson's Disease Rating Scale (UPDRS), Parts 3 (Motor Performance) and 4 (Disability). — 19.2; 17.6; 5.1; 2.9 score on a scale
Acute Lymphoblastic Leukemia
Primary: Number of Subjects With Event-Free Survival in Patients With Newly Diagnosed VHR B-ALL or High-risk Relapse of B-ALL 1 Year After Treatment. — 68.9 percentage of subjects
Irritable Bowel Syndrome · Abdominal Pain · Autonomic Nervous System Imbalance
Primary: Mean Change in IBS Symptom Severity From Baseline — 280; 320; 244; 316 score on a scale
Diabetes · Type 2 Diabetes
Primary: Change From Baseline in HbA1c at Week 52 [Noninferiority Analysis] — -1.26; -1.17 Percentage of HbA1c
Aggressive Non-Hodgkin Lymphoma · Indolent Non-Hodgkin Lymphoma · Recurrent Diffuse Large B-Cell Lymphoma
Primary: Number of Patients That Experienced a Dose Limiting Toxicity (DLT) — 0 Participants
Stress, Psychological
Primary: Determine the Feasibility of a Synchronous Web-based Health Education Program, of OUR Project. — 2.93 weeks attendance/month
Post-Cesarean Pain · Cesarean Section Complications
Primary: Mean Pain Score — 4.1; 4.2; 5.1; 5.2 score on a scale
Knee Osteoarthritis
Primary: Safety and Tolerability of Single IA Administration of 4P-004 at Escalating Doses in Participants With Knee OA. — 5; 5; 5; 6 participants
In-stent Restenosis
Primary: The Primary Safety Endpoint for the CVT-ISR Study: Freedom From Target Lesion Failure (TLF) Rate — 4; 1; 0; 3 Participants
Cancer · Pediatric Cancer
Primary: Survivor Care Knowledge Scale — 10.6; 11.2 score on a scale
This is a Phase I Study Conducted in Healthy Volunteers
Primary: Co-primary PK Endpoint Cmax: Maximum Serum Concentration — 12761.4; 12259.8 ng/mL
Human Immunodeficiency Virus · Depression · Sexually Transmitted Diseases
Primary: Prevalence of HIV and/or Chlamydia and/or Gonorrhoeae — 60; 70 Participants